Platelet receptors as therapeutic targets: Past, present and future
Platelet receptors as therapeutic targets: Past, present and future
复制标题
DOI：
10.1160/th16-12-0911
复制
发表时间：
2017-07-01
影响因子：
6.7
通讯作者：
Siess, Wolfgang
中科院分区：
文献类型：
--
作者：
Jamasbi, Janina;Ayabe, Keng;Siess, Wolfgang
抗血小板药物减少斑块破裂和侵蚀后的动脉血栓形成，预防支架血栓形成，并用于预防和治疗心肌梗死和缺血性中风。其中一些也可能有助于治疗不常见的疾病，如血栓性血小板减少性紫癜。本简要综述旨在涵盖抗血小板药物的当前和未来发展，这些药物干扰血管性血友病因子（VWF）与糖蛋白（GP）Ib α的相互作用，并针对GPVI、GPIIb/IIIa（整合素α（IIb）β（3））、凝血酶受体PAR-1和ADP受体P2 Y（12）。在不久的将来，人们对新型抗血小板药物的高度期望可能会得到满足，这种药物可以选择性地抑制动脉血栓形成而不干扰正常的止血。
Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ib alpha, and directed against GPVI, GPIIb/IIIa (integrin alpha(IIb)beta(3)), the thrombin receptor PAR-1, and the ADP receptor P2Y(12). The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.